Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2 Positive Operable Breast Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 688
- Registration Number
- NCT04547907
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Henan Cancer Hospital
- Registration Number
- NCT04538833
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04433156
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04430361
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT04341857
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
Phase 4
- Conditions
- Interventions
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04331626
Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT04293276
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT04280822
- Locations
- 🇨🇳
Henan Cancer Hospital (The Affiliated Cancer Hospital of Zhengzhou University), Zhengzhou, Henan, China
L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04268108
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Recruiting
- Conditions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04263935
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
© Copyright 2024. All Rights Reserved by MedPath